{
    "clinical_study": {
        "@rank": "70367", 
        "arm_group": [
            {
                "arm_group_label": "LY3053102", 
                "arm_group_type": "Experimental", 
                "description": "Single escalating dose (2 mg up to 400 mg) of LY3053102 administered subcutaneously (SQ)."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Single dose of placebo matching LY3053102 administered SQ."
            }
        ], 
        "brief_summary": {
            "textblock": "The main purpose of this study is to evaluate the safety and tolerability of the study drug\n      known as LY3053102 in healthy participants.  The study will also investigate how much of the\n      study drug gets into the blood stream and how long it takes the body to get rid of it.\n      Information about any side effects that may occur will also be collected.  The study is\n      expected to last approximately 8 weeks for each participant (up to 4 weeks from the\n      screening visit to the administration of study drug and an additional 4 weeks of follow up)."
        }, 
        "brief_title": "A Study of LY3053102 in Healthy Participants", 
        "completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy Volunteers", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Normal blood pressure\n\n          -  Female participants are not of child-bearing potential due to surgical sterilization\n             (hysterectomy or bilateral oophorectomy or tubal ligation) or menopause\n\n          -  Have a body mass index (BMI) of 18.5 to 40.0 kilograms per square meter (kg/m^2),\n             inclusive, at screening\n\n        Exclusion Criteria:\n\n          -  Have known allergies to LY3053102 or related compounds\n\n          -  Have a history of significant disease that may affect the actions of drugs or may\n             pose a risk when taking the study medication\n\n          -  Have a history of developing allergies, asthma, severe drug allergies (symptoms\n             including, but not limited to, itching, red rashes, sores on the skin, scaling and\n             shedding of skin), allergies or reactions to more than one drug, or have had bad\n             reactions to skin creams containing corticosteroids\n\n          -  Heavy smokers (more than 10 cigarettes a day)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "53", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 26, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01736241", 
            "org_study_id": "14514", 
            "secondary_id": "I6I-MC-LMRA"
        }, 
        "intervention": [
            {
                "arm_group_label": "LY3053102", 
                "description": "Administered SQ", 
                "intervention_name": "LY3053102", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Administered SQ", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "July 12, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Singapore", 
                    "country": "Singapore", 
                    "zip": "117597"
                }, 
                "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
            }
        }, 
        "location_countries": {
            "country": "Singapore"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Single-Dose, Dose-Escalation Study to Determine the Safety, Tolerability, and Pharmacokinetics of LY3053102 in Healthy Subjects", 
        "overall_official": {
            "affiliation": "Eli Lilly and Company", 
            "last_name": "Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Singapore: Health Sciences Authority"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Number of Participants with One or More Adverse Events (AEs) or Any Serious AEs", 
            "safety_issue": "Yes", 
            "time_frame": "Pre-dose up to Day 31"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01736241"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Pharmacokinetics (PK): Area Under the Concentration Curve (AUC) of LY3053102", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose up to Day 31"
            }, 
            {
                "measure": "Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3053102", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose up to Day 31"
            }, 
            {
                "measure": "Number of Participants Developing Anti-LY3053102 Antibodies", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose up to Day 31"
            }
        ], 
        "source": "Eli Lilly and Company", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Eli Lilly and Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}